Publication:
Comparison between sleeve gastrectomy and exenatide on type 2 diabetic patients

dc.contributor.authorElbasan, Onur
dc.contributor.authorŞişman, Pınar
dc.contributor.authorPeynirci, Hande
dc.contributor.authorYabacı, Ayşegül
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorERSOY, CANAN
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi.
dc.contributor.researcheridAAH-8861-2021
dc.date.accessioned2024-07-03T11:05:24Z
dc.date.available2024-07-03T11:05:24Z
dc.date.issued2020-02-28
dc.description.abstractBackground: Diabetes and obesity are major causes of mortality and morbidity that are increasing all over the world. As obesity is a major risk factor for type 2 diabetic patients, weight loss is important in the treatment of type 2 diabetic patients. In our study, our aim was to evaluate the effects of exenatide and laparoscopic sleeve gastrectomy (LSG) in obese type 2 diabetic patients on the clinical and laboratory parameters.Methods: Twenty-five LSG and 25 exenatide patients followed up in our outpatient clinic were involved in the study.Results: At the end of the 6-month follow-up, weight loss was similar to 35.4 kg in the surgery group and 11.5 kg in the exenatide group. Although postprandial glucose and hemoglobin A1c were significantly decreased in both groups, the decrease was significantly higher in LSG group compared to the exenatide group. Although there was no significant change in fasting blood glucose (FBG) in the exenatide group, there was a significant decrease in FBG in LSG group.Conclusion: LSG is a method that should be performed up on indication and much more radical compared to exenatide administration, but appears to be a more efficient application that corrects diabetes- and obesity-related metabolic parameters compared to exenatide therapy in type 2 diabetic obese patients.
dc.identifier.doi10.1089/bari.2019.0041
dc.identifier.endpage204
dc.identifier.issn2168-023X
dc.identifier.issue4
dc.identifier.startpage199
dc.identifier.urihttps://doi.org/10.1089/bari.2019.0041
dc.identifier.urihttps://hdl.handle.net/11452/42819
dc.identifier.volume15
dc.identifier.wos000517902000001
dc.indexed.wosWOS.SCI
dc.indexed.wosWOS.SSCI
dc.language.isoen
dc.publisherMary Ann Liebert
dc.relation.journalBariatric Surgical Practice And Patient Care
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCardiovascular risk-factors
dc.subjectBariatric surgery
dc.subjectObese-patients
dc.subjectHepatic biomarkers
dc.subjectReceptor agonists
dc.subjectInterim analysis
dc.subjectMedical therapy
dc.subjectEfficacy
dc.subjectManagement
dc.subjectWeight
dc.subjectBariatric surgery
dc.subjectExenatide
dc.subjectObesity
dc.subjectT2dm
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectNursing
dc.subjectSurgery
dc.titleComparison between sleeve gastrectomy and exenatide on type 2 diabetic patients
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication1a528bc6-7850-41a4-a7cc-1b7f1aded115
relation.isAuthorOfPublication.latestForDiscovery1a528bc6-7850-41a4-a7cc-1b7f1aded115

Files

Collections